iMab : Technology for Targeting Cytosolic Proteins


Full-length IgG antibodies cannot cross cell membranes of living cells; this limits their use for direct targeting of cytosolic proteins. However disease-associated protein–protein interactions (PPIs) occur mainly in the cytosol of cells. We are now developing an innovative technology, called iMab (internalizing & PPI (protein-protein interaction) interfering antibody). iMab technology enables full-length IgG antibodies to directly target cytosolic proteins. It is composed of multifunctional VL and VL domains. As a proof-of-concept, we are now developing iMab targeting the mutant Ras protein.


There are no reviews yet.

Be the first to review “iMab : Technology for Targeting Cytosolic Proteins”


We're not around right now. But you can send us an email and we'll get back to you, asap.


©2010-2021 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?